Immuron Limited Adr stock is traded at $0.9216, with a volume of 10,805. It is down -0.63% in the last 24 hours and down -11.38% over the past month. Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.
Previous Close:
$0.9274
Open:
$0.94
24h Volume:
10,805
Relative Volume:
0.61
Market Cap:
$7.44M
Revenue:
$4.83M
Net Income/Loss:
-$2.99M
P/E Ratio:
-
EPS:
-$0.4804
Net Cash Flow:
-$2.83M
1W Performance:
+8.44%
1M Performance:
-11.38%
6M Performance:
+15.06%
1Y Performance:
-42.76%
1-Day Range:
$0.915$0.97
1-Week Range:
$0.78$0.97
52-Week Range:
$0.6765$1.99
Immuron Limited Adr Stock (IMRN) Company Profile
Market Cap
Revenue
Net Income
Cash Flow
EPS